Cardiotoxicity of Cancer Chemotherapy: Identification, Prevention and Treatment

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2017 Sep 23

PMID 28936442

Citations 21

Authors

Diwakar Jain

Tauseef Ahmad

Mitchel Cairo

Wilbert Aronow

Affiliations

Soon will be listed here.

Abstract

Cardiotoxicity is an important complication of several cancer therapeutic agents. Several well established and newer anticancer therapies such as anthracyclines, trastuzumab and other HER2 receptor blockers, antimetabolites, alkylating agents, tyrosine kinase inhibitors (TKIs), angiogenesis inhibitors, and checkpoint inhibitors are associated with significant cardiotoxicity. Cardiovascular imaging employing radionuclide imaging, echocardiography and magnetic resonance imaging are helpful in early detection and prevention of overt heart failure secondary to cardiotoxicity of cancer therapy. An understanding of the mechanism of the cardiotoxicity of cancer therapies can help prevent and treat their adverse cardiovascular consequences. Clinical implementation of algorithms based upon cardiac imaging and several non-imaging biomarkers can prevent cardiac morbidity and mortality associated with the use of cardiotoxic cancer therapies.

Citing Articles

Artificial intelligence: Applications in cardio-oncology and potential impact on racial disparities.

Echefu G, Shah R, Sanchez Z, Rickards J, Brown S Am Heart J Plus. 2024; 48:100479.

PMID: 39582990 PMC: 11583718. DOI: 10.1016/j.ahjo.2024.100479.

Knowledge, attitudes, and practice of physicians and pharmacists regarding the prevention and treatment of cardiovascular toxicity associated with cancer treatment.

Li C, Yan W, Gao M, Zhang Z, Zhao L, Ma J Sci Rep. 2024; 14(1):20122.

PMID: 39209910 PMC: 11362540. DOI: 10.1038/s41598-024-71015-z.

Cardiovascular Complications of Pan-Cancer Therapies: The Need for Cardio-Oncology.

Chen M, Xue J, Wang M, Yang J, Chen T Cancers (Basel). 2023; 15(11).

PMID: 37297017 PMC: 10252624. DOI: 10.3390/cancers15113055.

Cardio-Oncology: Mechanisms, Drug Combinations, and Reverse Cardio-Oncology.

Liang Z, He Y, Hu X Int J Mol Sci. 2022; 23(18).

PMID: 36142538 PMC: 9501315. DOI: 10.3390/ijms231810617.

Analysis of Epidemiological Characteristics of New Cardiovascular Diseases in Cancer Patients with Cardiovascular Disease.

Zhang G, Zhang Y, Li W J Oncol. 2022; 2022:5157398.

PMID: 36090898 PMC: 9452938. DOI: 10.1155/2022/5157398.

References

Zhang S, Liu X, Bawa-Khalfe T, Lu L, Lyu Y, Liu L . Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012; 18(11):1639-42. DOI: 10.1038/nm.2919. View

Von Hoff D, Layard M, Basa P, Davis Jr H, Von Hoff A, Rozencweig M . Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979; 91(5):710-7. DOI: 10.7326/0003-4819-91-5-710. View

Wolchok J . PD-1 Blockers. Cell. 2015; 162(5):937. DOI: 10.1016/j.cell.2015.07.045. View

Walker J, Bhullar N, Fallah-Rad N, Lytwyn M, Golian M, Fang T . Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J Clin Oncol. 2010; 28(21):3429-36. DOI: 10.1200/JCO.2009.26.7294. View

Saito K, Takeda K, Imanaka-Yoshida K, Imai H, Sekine T, Kamikura Y . Assessment of fatty acid metabolism in taxan-induced myocardial damage with iodine-123 BMIPP SPECT: comparative study with myocardial perfusion, left ventricular function, and histopathological findings. Ann Nucl Med. 2003; 17(6):481-8. DOI: 10.1007/BF03006439. View

Fallah-Rad N, Walker J, Wassef A, Lytwyn M, Bohonis S, Fang T . The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated.... J Am Coll Cardiol. 2011; 57(22):2263-70. DOI: 10.1016/j.jacc.2010.11.063. View

Nilsson G, Holmberg L, Garmo H, Duvernoy O, Sjogren I, Lagerqvist B . Distribution of coronary artery stenosis after radiation for breast cancer. J Clin Oncol. 2011; 30(4):380-6. DOI: 10.1200/JCO.2011.34.5900. View

Chu T, Rupnick M, Kerkela R, Dallabrida S, Zurakowski D, Nguyen L . Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007; 370(9604):2011-9. PMC: 2643085. DOI: 10.1016/S0140-6736(07)61865-0. View

Schwartz R, McKenzie W, Alexander J, Sager P, Dsouza A, Manatunga A . Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987; 82(6):1109-18. DOI: 10.1016/0002-9343(87)90212-9. View

10.

Yu C, Chopra I, Ha E . A novel melanoma therapy stirs up a storm: ipilimumab-induced thyrotoxicosis. Endocrinol Diabetes Metab Case Rep. 2015; 2015:140092. PMC: 4330494. DOI: 10.1530/EDM-14-0092. View

11.

Chintalgattu V, Rees M, Culver J, Goel A, Jiffar T, Zhang J . Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity. Sci Transl Med. 2013; 5(187):187ra69. PMC: 3833098. DOI: 10.1126/scitranslmed.3005066. View

12.

Jurcut R, Wildiers H, Ganame J, Dhooge J, De Backer J, Denys H . Strain rate imaging detects early cardiac effects of pegylated liposomal Doxorubicin as adjuvant therapy in elderly patients with breast cancer. J Am Soc Echocardiogr. 2008; 21(12):1283-9. DOI: 10.1016/j.echo.2008.10.005. View

13.

Lee J, Lee H, Shin W, Chae J, Choi J, Kim S . Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Nat Commun. 2016; 7:13354. PMC: 5095608. DOI: 10.1038/ncomms13354. View

14.

Gianni L, Pienkowski T, Im Y, Roman L, Tseng L, Liu M . Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2011; 13(1):25-32. DOI: 10.1016/S1470-2045(11)70336-9. View

15.

Panjrath G, Jain D . Trastuzumab-induced cardiac dysfunction. Nucl Med Commun. 2007; 28(2):69-73. DOI: 10.1097/MNM.0b013e328025ae04. View

16.

Rowinsky E, McGuire W, Guarnieri T, Fisherman J, Christian M, Donehower R . Cardiac disturbances during the administration of taxol. J Clin Oncol. 1991; 9(9):1704-12. DOI: 10.1200/JCO.1991.9.9.1704. View

17.

McGale P, Darby S, Hall P, Adolfsson J, Bengtsson N, Bennet A . Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother Oncol. 2011; 100(2):167-75. DOI: 10.1016/j.radonc.2011.06.016. View

18.

Dutcher J, Atkins M, Margolin K, Weiss G, Clark J, Sosman J . Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines. Med Oncol. 2002; 18(3):209-19. DOI: 10.1385/MO:18:3:209. View

19.

Frickhofen N, Beck F, Jung B, Fuhr H, Andrasch H, Sigmund M . Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol. 2002; 13(5):797-801. DOI: 10.1093/annonc/mdf035. View

20.

Dazzi H, Kaufmann K, Follath F . Anthracycline-induced acute cardiotoxicity in adults treated for leukaemia. Analysis of the clinico-pathological aspects of documented acute anthracycline-induced cardiotoxicity in patients treated for acute leukaemia at the University Hospital of.... Ann Oncol. 2001; 12(7):963-6. DOI: 10.1023/a:1011196910325. View